CMPS

COMPASS Pathways Plc - American Depository…

6.41 USD

Last updated Dec 8, 21:54 UTC

Yesterday HIGH

$6.15

Yesterday LOW

$5.49

52w HIGH

$11.48

52w LOW

$5.01

EPS

-0.67

PE

-9.57

Next Earnings

Feb 27, 2024

Overview News Government Trades

COMPASS Pathways Plc - American Depository… stock is up 15.08% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 December’s closed higher than November.

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression. The company was formerly known as COMPASS Rx Limited.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

compasspathways.com

Benzinga Newsdesk

Thu Oct 26, 2023

'California Activists Plan To File New Psychedelics Legalization Ballot Initiative This Week' - Marijuana Moment

https://www.marijuanamoment.net/california-activists-plan-to-file-new-psychedelics-legalization-ballot-initiative-this-week/Activists in California say they'll submit a proposed ballot measure this week that would
Benzinga Newsdesk

Thu Oct 26, 2023

COMPASS Pathways Announces CFO Transition; Mike Falvey, Chief Financial Officer, Will Depart The Company On November 3, 2023; Mary-Rose Hughes Will Assume The Role Of Interim CFO Effective Today

COMPASS Pathways plc (NASDAQ:CMPS) ("COMPASS" or the "company"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Mike Falvey, Chief
Lara Goldstein

Sun Oct 22, 2023

Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted

Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts
Lara Goldstein

Mon Oct 16, 2023

Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution
Lara Goldstein

Fri Oct 6, 2023

Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares
Benzinga Insights

Thu Oct 5, 2023

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 369 companies hit new 52-week lows.
Benzinga Insights

Tue Oct 3, 2023

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 647 companies set new 52-week lows.
Lara Goldstein

Mon Oct 2, 2023

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.
Lara Goldstein

Tue Sep 26, 2023

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge
Lara Goldstein

Mon Sep 18, 2023

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next